DISSECTIONING RISK FACTORS FOR MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE MYELOID LEUKEMIA (AML) AFTER AUTOTRANSPLANTS FOR PLASMA CELL MYELOMA AND LYMPHOMAS

被引：0
|
作者：
Hashmi, S. [1 ]
Dean, R. M. [2 ]
Shaw, B. [3 ]
Brazauskas, R. [3 ]
Millard, H. [3 ]
Battiwalla, M. [4 ]
Savani, B. [5 ]
Flowers, M. E. [6 ]
Cooke, K. R. [7 ]
Hamilton, B. K. [2 ]
Kalaycio, M. [8 ]
Radivoyevitch, T. [9 ]
Litzow, M. R. [10 ,11 ]
Gale, R. P. [12 ]
机构：
[1] Mayo Clin, Bone Marrow Transplant Program, Rochester, MN USA
[2] Taussig Canc Inst, Dept Hematol Oncol & Blood Disorders, Cleveland, OH USA
[3] MCW, CIBMTR, Milwaukee, WI USA
[4] NHLBI, Hematol Branch, Bethesda, MD 20892 USA
[5] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
[6] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[7] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Pediat Blood & Marrow Transplantat Program, Baltimore, MD USA
[8] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
[9] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH 44106 USA
[10] Mayo Clin, Div Hematol, Rochester, MN USA
[11] Mayo Clin, Transplant Ctr, Rochester, MN USA
[12] Imperial Coll London, Dept Med, Sect Hematol, London, England
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30174-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
61
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [21] Clinical relevance of circulating myeloperoxidase (MPO) in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Jilani, I
    Vincenti, T
    Faraji, H
    Giles, FJ
    Estey, E
    Kantarjian, HM
    Albitar, M
    BLOOD, 2004, 104 (11) : 305A - 305A
  • [22] Immediate Allogeneic Hematopoietic Cell Transplantation (HCT) in Acute Myeloid Leukemia (AML) Arising From Myelodysplastic Syndrome (MDS)
    Kim, Sung-Doo
    Choi, Yunsuk
    Park, Young-Hun
    Lee, Jae Seok
    Kim, Dae-Young
    Lee, Jung-Hee
    Lee, Kyoo-Hyung
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Jung, Ah Rang
    Lee, Je-Hwan
    BLOOD, 2011, 118 (21) : 888 - 889
  • [23] MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes
    Ohanian, Maro
    Rozovski, Uri
    Kantarjian, Hagop M.
    Loghavi, Sanam
    Huh, Yang O.
    Abruzzo, Lynne
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Andreeff, Michael
    Kornblau, Steven M.
    Borthakur, Gautam
    Nguyen, Martin
    Stingo, Francesco
    Hu, Peter
    Fox, Patricia
    Medeiros, L. Jeffrey
    Estrov, Zeev
    Bueso-Ramos, Carlos E.
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [24] MORPHOLOGY OF T(8-21) ACUTE MYELOID-LEUKEMIA MYELODYSPLASTIC SYNDROME (AML/MDS)
    HUTCHISON, R
    LAWRENCE, D
    MACCALLUM, J
    VARNEY, J
    DEHORITY, D
    WURSTERHILL, D
    BLOOMFIELD, C
    DAVEY, F
    LABORATORY INVESTIGATION, 1991, 64 (01) : A74 - A74
  • [25] Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia
    Feldman, EJ
    Seiter, KP
    Ahmed, T
    Baskind, P
    Arlin, ZA
    LEUKEMIA, 1996, 10 (01) : 40 - 42
  • [26] Transformation of myelodysplastic syndrome (MDS) to hypocellular Acute Myeloid Leukemia (AML) post renal transplant.
    Hasni, K
    Gunnala, V
    Shah, M
    Hoang, T
    Kung, SC
    Brodsky, I
    Kumar, MA
    Heifets, M
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 923A - 923A
  • [27] Detection of FLT3 gene mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Andrei, A.
    Crisan, D.
    Meng, X.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2006, 8 (05): : 639 - 639
  • [28] Combinations of topotecan and liposomal daunorubicin (Daunoxome) in refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Giles, FJ
    Kantarjian, HM
    Cortes, JE
    Koller, C
    Thomas, D
    O'Brien, SM
    Estey, E
    Beran, M
    BLOOD, 1999, 94 (10) : 230B - 230B
  • [29] Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)
    Kyo, Taiichi
    Yoshida, Noriaki
    Kyo, Kouhei
    Okatani, Takeshi
    Itagaki, Mitsuhiro
    Yuasa, Hiromi
    Iwato, Koji
    Asaoku, Hideki
    Katayama, Yuuta
    BLOOD, 2010, 116 (21) : 1209 - 1210
  • [30] Tipifarnib in combination with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
    Ravandi-Kashani, F.
    Kantarjian, H.
    Garcia-Manero, G.
    O'Brien, S.
    Verstovsek, S.
    Estrov, Z.
    Faderl, S.
    Giles, F.
    Wright, J.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 351S - 351S
12345